FAKTOR-OPTIONSSCHEIN - ELI LILLY & CO | Real-time Bid/Ask 05:44:51 2024-07-11 am EDT | ||
| 461.56 EUR / 462.51 EUR | +2.13% |
|
| Current month | +8.43% | ||
| 1 month | +37.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-10 | 452.4 | +5.89% |
| 24-07-09 | 427.2 | +3.50% |
| 24-07-08 | 412.8 | +7.27% |
| 24-07-05 | 384.8 | -0.69% |
| 24-07-04 | 387.5 | -5.41% |
Delayed Quote Börse Stuttgart
Last update July 10, 2024 at 01:39 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MA887R |
| ISIN | DE000MA887R9 |
| Date issued | 2021-07-27 |
| Strike | 705 $ |
| Maturity | Unlimited |
| Parity | 0.48 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 452.4 € |
|---|---|
| Lowest since issue | 6.28 € |
| Spread | 1.01 € |
| Spread % | 0.22% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
877.2
USD
Spread / Average Target
-6.66%
- Stock Market
- Certificates
- Certificat
